- Record: found
- Abstract: not found
- Article: not found
The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock ,
Douglas W. Ball ,
Marianna L. Zahurak ,
Barry D. Nelkin ,
Vivek Subbiah ,
Shabina Ahmed ,
Ashley O'Connor ,
Enusha Karunsena ,
Rose M. Parkinson ,
Justin A. Bishop ,
Yoonji Ha ,
Rajni Sharma ,
Christopher D. Gocke ,
Ralph Zinner ,
Michelle A. Rudek ,
Steven I. Sherman ,
Nilofer S. Azad
June 11 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals
through RAS/RAF/MEK signaling. We evaluated the safety and efficacy of the VEGF receptor
inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC.